Trials / Completed
CompletedNCT01525043
Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow
Randomized, Parallel-Group, Open Label, Dose Finding Study to Evaluate the Efficacy of Synera Patch Compared to Naproxen Sodium for the Treatment of Lateral and Medial Epicondylitis of the Elbow
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- International Clinical Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the this study is to evaluate the sfaety and efficacy of Synera(R)for patients with lateral and medial epicondylitis and compare it to Naproxen sodius.
Detailed description
The objective of this single center is to evaluate the safety and efficacy of Synera ® in lateral and medial epicondylitis . This is an open-label, comaparative study study where the subjects will be randomized to one of the following groups: 1. Synera patch ®: A single patch applied for 4 hours twice daily approximatey 12 hrs apart to the medial or lateral side of the index elbow 2. Synera patch ®: A single patch applied for 12 hours/day to the medial or lateral side of the index elbow 3. Naproxen Sodium: 500mg bid
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naproxen | Naproxen 500mg BID for the first 2 weeks |
| DRUG | Synera patch twice daily | 1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks |
| DRUG | Synera patch for 12hrs/day | 1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks |
| DRUG | Naproxen | 500mg bid |
| DRUG | Synera | Topical appication of single patch to elbow for 12hrs/day |
| DRUG | Synera | Single patch applied to elbow for 4hrs/twice daily |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Completion
- 2013-09-01
- First posted
- 2012-02-02
- Last updated
- 2014-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01525043. Inclusion in this directory is not an endorsement.